ClinicalTrials.gg
CompletedNCT02232529Updated Feb 24, 2015

Pharmacokinetic Study of MIN-101 in Healthy Subjects

A Phase 1 interventional study of MIN-101 and Placebo in Schizophrenia, sponsored by Minerva Neurosciences. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-02-24.

Sponsored by Minerva Neurosciences · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 110 studies in Schizophrenia with a site in United Kingdom — 10 open to participants now, 10 under way, none of them phase 3. Schizophrenia · United Kingdom.

Enrollment
66th of 91
32 · median 80
Started
2014
with 8 others
Phase 1
23 of 110
1 open now
Registered
54th of 110
by date

Among the 110 studies in Schizophrenia with a site in United Kingdom, this one is the 66th largest by enrollment of the 91 interventional ones that give a count, is one of 9 that started in 2014, is one of 23 in phase 1, and was the 54th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

10 of the 110 studies in Schizophrenia with a site in United Kingdom are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 110 studies in Schizophrenia with a site in United Kingdom, or all of them as a file.
02

Study summary

The aim of the study is to assess how MIN-101 is taken up by the body when given in different amounts and in different formulations. The drug will be given as a single dose in Part 1 of the study and during Part 2 of the study as multiple dose, once daily for 7 days. The ultimate aim is to find an optimal formulation which can be developed as a once daily dose for the treatment of schizophrenia.

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • modified release formulation
  • pharmacokinetics
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

  • Healthy males (Part 1 and Part 2) or non-pregnant, non-lactating healthy females (Part 2 only)
  • (BMI) of 18.0 to 30.0 kg/m2
  • Must be CYP2D6 Extensive metabolizer
  • Must be willing and able to communicate and participate in the whole study
  • Must provide written
  • Must agree to use an adequate method of

Key Exclusion Criteria:

  • Subjects who have > 430 in male, > 450 in female confirmed by a repeat
  • Any family history of sudden cardiac death and Torsade de Points
  • No personal or family history of unexplained presyncope, syncope or orthostatic hypotension
  • History of any drug or alcohol abuse in the past 2 years
  • History or evidence of any medically diagnosed psychiatric disorders
  • Suicidal tendencies or history of suicidal attempts
  • Regular alcohol consumption in males >21 units per week and females >14 units per week (1 unit = ½ pint beer, 25 mL of 40% spirit or a 125 mL glass of wine)
  • Current smokers and those who have smoked within the last 12 months. A breath carbon monoxide reading of greater than 10 ppm at screening
  • Females of who are pregnant or lactating (female subjects must have a negative urine pregnancy test at admission)
  • Clinically significant abnormal biochemistry, haematology or urinalysis as judged by the investigator
  • Positive drugs of abuse test result
  • Positive surface antigen (HBsAg), virus antibody (HCV Ab) or (HIV) results
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Part 1: MIN-101

    MIN-101 modified release formulation (MR),single oral dose between 16 and 64 mg

    Drug: MIN-101

  • Experimental
    Part 2: MIN-101 low dose

    MIN-101 single daily oral dose, low dose MR formulation, from Day 1 to Day 7

    Drug: MIN-101

  • Placebo comparator
    Part 2: placebo

    placebo MIN-101 daily oral dose from Day 1 to Day 7

    Drug: Placebo

  • Experimental
    Part 2: MIN-101 high dose

    MIN-101 single daily oral dose, low dose MR formulation, from Day 1 to Day 7

    Drug: MIN-101

Interventions

06

What researchers measure

Primary outcomes

  1. Part 1 Pharmacokinetic profile of MIN-101 and its main metabolites (AUC (0-last), Tmax, Cmax, AUC (0-inf), %AUCextrap, Lambda z, T1/2 and parent:metabolites ratio

    Time frame: predose and 0.5h, 1h, 1.5h, 2h, 2.5h, 3H, 4H, 6h, 8h, 10h, 12h, 14h, 16h, 20h, 24h, 48h and 72h post-dose

  2. Part 2 - Pharmacokinetic profile of MIN-101 and its main metabolites - Absolute QT intervals and QT intervals corrected using Fridericia formula (QTcF)

    Time frame: predose to Day 8

Secondary outcomes

  1. Part 1 Safety and tolerability (incidence of adverse events, safety laboratory, 12-lead ECGs, vital signs, physical examination) -

    Time frame: from predose up to 72 h post dosing

  2. Part 1 Pharmacokinetic profile of MIN-101 in fed and fasted state

    Time frame: from predose up to 72 h post dosing

  3. Part 2 Change from baseline in ECG parameters other than QT/QTc

    QTcB, QRS, RR, PR intervals, U waves, T waves morphology

    Time frame: from predose up to Day 8

  4. Part 2 Change from baseline in heart rate and blood pressure

    Time frame: from predose up to Day 8

  5. Part 2 Incidence of QT/QTc changes from baseline greater than 30 and 60 ms post dose

    Time frame: from predose up to Day 8

  6. Part 2 Incidence of QTc values greater than 450, 480 and 500 ms post dose

    Time frame: from predose up to Day 8

  7. Part 2 Safety and tolerability of MIN-101 (adverse events occurrence, physical examination, safety laboratory tests)

    Time frame: from predose up to Day 8

Other outcomes

  1. Changes in sleep architecture and sleep continuity

    Time frame: Day 6

07

Study locations

1 site
  • Quotient Clinical
    Ruddington, Nottingham, NG116JS, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2014, a primary completion of Feb 2015 and a completion of Feb 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 3, 2014
First posted
Sep 5, 2014
Start
Sep 2014
Primary completionActual
Feb 2015
CompletionActual
Feb 2015
Last update
Feb 24, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02232529
Lead sponsor
Minerva Neurosciences
Responsible party
Sponsor
First posted
Sep 5, 2014
Start date
Sep 2014
Primary completion
Feb 2015
Completion
Feb 2015
Last update
Feb 24, 2015

Study contacts

Pui Leung, M.D
principal investigator · Quotient Clinical

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Roluperidone

Start the discussion